postexposur
prophylaxi
middl
east
respiratori
syndrom
coronaviru
outbreak
healthcar
worker
highrisk
exposur
preisol
pneumonia
u
r
effect
postexposur
prophylaxi
pep
strategi
may
limit
spread
infect
howev
consensu
regard
pep
middl
east
respiratori
syndrom
coronaviru
merscov
infect
studi
assess
efficaci
ribavirin
lopinavirritonavir
pep
healthcar
worker
hcw
expos
patient
sever
merscov
preisol
pneumonia
safeti
pep
regimen
assess
hcw
highrisk
exposur
merscov
preisol
pneumonia
retrospect
enrol
hcw
receiv
pep
therapi
classifi
pep
group
pep
therapi
associ
decreas
risk
infect
sever
advers
event
pep
therapi
howev
consensu
regard
pep
middl
east
respiratori
syndrom
coronaviru
merscov
infect
studi
assess
efficaci
ribavirin
lopinavirritonavir
pep
healthcar
worker
hcw
expos
patient
sever
merscov
preisol
pneumonia
safeti
pep
regimen
assess
hcw
highrisk
exposur
merscov
preisol
pneumonia
retrospect
enrol
hcw
receiv
pep
therapi
classifi
pep
group
pep
therapi
associ
decreas
risk
infect
sever
advers
event
pep
therapi
healthcar
infect
societi
publish
elsevi
ltd
right
reserv
spread
infect
individu
healthcar
set
princip
contribut
infect
outbreak
healthcar
worker
hcw
high
risk
acquir
emerg
infect
care
patient
among
laboratoryconfirm
case
middl
east
respiratori
syndrom
coronaviru
merscov
outbreak
south
korea
hcw
expos
merscov
healthcar
facil
thirti
hcw
infect
merscov
cours
treatment
without
know
whether
patient
infect
merscov
approv
postexposur
prophylaxi
pep
therapi
prevent
merscov
infect
object
studi
assess
efficaci
pep
therapi
hcw
expos
patient
sever
merscov
preisol
pneumonia
safeti
pep
regimen
also
evalu
sampl
merscov
pneumonia
case
studi
set
studi
popul
woman
henceforth
known
patient
admit
hospit
complain
back
pain
time
admiss
patient
pneumonia
fever
last
day
two
day
later
patient
transfer
intens
care
unit
receiv
endotrach
intub
sinc
diagnosi
merscov
infect
suspect
period
hcw
use
appropri
person
protect
equip
ppe
specif
pathogen
identifi
test
merscov
infect
conduct
realtim
revers
transcriptaseepolymeras
chain
reaction
rrtepcr
strongli
posit
merscov
patient
cycl
threshold
c
valu
envelop
protein
gene
open
read
frame
gene
patient
diagnos
merscov
rapid
contact
trace
perform
possibl
contact
exposur
divid
two
group
highrisk
nonhighrisk
exposur
group
hcw
highrisk
exposur
isol
immedi
offer
oral
ribavirin
viramid
capsul
ilsung
pharmaceut
seoul
south
korea
lopinavirritonavir
kaletra
abbvi
inc
north
chicago
il
usa
pep
protocol
initi
day
last
unprotect
exposur
patient
pep
therapi
administ
day
last
exposur
accord
incub
period
diseas
ribavirin
administ
oral
load
dose
mg
follow
mg
everi
h
day
mg
everi
h
day
lopinavirritonavir
administ
oral
dose
mg
everi
h
day
laboratori
test
hcw
pep
group
perform
day
treatment
initi
hcw
receiv
pep
therapi
also
underw
twopoint
sputum
screen
merscov
rrtepcr
improv
detect
unrecogn
merscov
infect
pep
group
enzymelink
immunosorb
assay
elisa
euroimmun
germani
also
perform
detect
merscov
immunoglobulin
g
igg
complet
pep
therapi
control
group
select
four
hospit
superspread
event
retrospect
select
retrospect
compar
studi
conduct
five
hospit
south
korea
hospit
a
secondari
referr
hospit
wherea
hospit
e
tertiari
referr
hospit
hospit
correspond
merscov
preisol
pneumonia
patient
patient
aee
preisol
pneumonia
patient
visit
particip
hospit
without
know
infect
merscov
c
data
avail
five
merscov
preisol
pneumonia
patient
c
valu
five
patient
similar
hcw
unprotect
exposur
patient
merscov
preisol
pneumonia
enrol
five
hospit
may
juli
includ
hcw
highrisk
exposur
hcw
hospit
treat
pep
repres
pep
group
hcw
hospit
receiv
pep
classifi
nonpep
group
hcw
nonpep
group
isol
monitor
develop
merslik
symptom
day
date
exposur
patient
mer
incid
merscov
infect
compar
group
mer
outbreak
south
korea
hospit
conduct
contact
survey
evalu
exposur
level
five
investig
hospit
individu
collect
data
review
potenti
exposur
epidemiolog
data
obtain
medic
record
review
person
interview
may
juli
definit
merscov
infect
confirm
use
rrtepcr
preisol
pneumonia
defin
patient
diagnos
pneumonia
prior
quarantin
without
knowledg
merscov
infect
highrisk
exposur
arbitrarili
defin
follow
direct
care
without
aerosolgener
procedur
inappropri
ppe
unprotect
exposur
patient
merscov
preisol
pneumonia
aerosolgener
procedur
definit
appropri
ppe
base
previou
recommend
absenc
part
ppe
constitut
unprotect
exposur
defin
follow
aerosolgener
procedur
airway
suction
applic
highflow
instrument
bronchoscopi
endotrach
intub
tracheostomi
nebul
treatment
sputum
induct
posit
pressur
ventil
manual
ventil
cardiopulmonari
resuscit
sever
hcw
one
type
exposur
duplic
exposur
record
baselin
characterist
pep
nonpep
group
compar
use
c
test
fisher
exact
test
categor
variabl
student
ttest
mannewhitney
utest
continu
variabl
merscov
attack
rate
compar
group
use
fisher
exact
test
categor
variabl
present
frequenc
proport
continu
variabl
present
mean
standard
deviat
median
interquartil
rang
iqr
multivari
analysi
conduct
due
small
sampl
size
odd
ratio
confidenti
interv
ci
also
calcul
variabl
pvalu
twotail
p
consid
statist
signific
pasw
version
spss
inc
chicago
il
usa
use
statist
analys
pep
group
studi
inform
efficaci
pep
merscov
infect
unknown
advers
effect
possibl
individu
particip
voluntari
particip
provid
written
inform
consent
prior
initi
pep
therapi
studi
approv
institut
review
board
respect
hospit
hcw
unprotect
exposur
merscov
preisol
pneumonia
patient
identifi
five
particip
hospit
hcw
met
definit
highrisk
exposur
figur
twentytwo
hcw
classifi
pep
group
remain
hcw
classifi
nonpep
group
baselin
characterist
gener
similar
two
group
tabl
except
median
age
pep
group
significantli
lower
nonpep
group
none
hcw
highrisk
exposur
worn
respir
isol
gown
goggl
facial
shield
common
type
exposur
merscov
via
direct
care
without
aerosolgener
procedur
merscov
patient
follow
airway
suction
nebul
treatment
eighteen
hcw
expos
merscov
via
direct
care
without
aerosolgener
procedur
nonpep
group
one
pep
group
p
six
hcw
develop
merscov
infect
attack
rate
lower
pep
group
compar
nonpep
group
vs
ci
p
instanc
merscov
infect
pep
group
six
hcw
infect
merscov
one
expos
two
event
cardiopulmonari
resuscit
airway
suction
pep
therapi
signific
factor
ci
p
reduc
risk
merscov
infect
pep
group
pep
therapi
initi
within
median
h
rang
h
unprotect
exposur
merscov
preisol
pneumonia
patient
hcw
receiv
pep
therapi
median
durat
day
iqr
day
pep
therapi
gener
well
toler
although
minor
advers
effect
report
overal
hcw
pep
group
report
one
symptom
cours
therapi
common
symptom
diarrhoea
nausea
stomat
fever
twenti
hcw
pep
group
underw
laboratori
test
anaemia
leucopenia
observ
nine
eight
hcw
respect
pep
therapi
hyperbilirubinaemia
observ
hcw
howev
liver
function
test
within
normal
rang
elev
total
bilirubin
decreas
valu
haemoglobin
leucocyt
normal
complet
pep
therapi
merscov
rrtepcr
perform
sampl
obtain
hcw
pep
group
immedi
seven
day
complet
pep
protocol
test
result
neg
serum
sampl
collect
six
week
unprotect
highrisk
exposur
neg
merscov
antibodi
preliminari
studi
assess
efficaci
safeti
pep
hcw
unprotect
highrisk
exposur
patient
diagnos
sever
merscov
preisol
pneumonia
despit
sever
exposur
mer
cov
infect
occur
pep
group
pep
therapi
appear
reduc
risk
merscov
hcw
unprotect
highrisk
exposur
mer
patient
studi
infect
rate
merscov
estim
among
hcw
fourfold
averag
estim
household
transmiss
rate
main
mode
merscov
transmiss
via
respiratori
droplet
indic
hcw
particularli
high
risk
merscov
infect
therefor
highrisk
exposur
aerosolgener
procedur
includ
tracheal
intub
without
appropri
ppe
may
increas
risk
merscov
contamin
decid
administ
prophylact
antivir
agent
hcw
highrisk
exposur
mer
patient
take
variou
factor
consider
although
current
recommend
merscov
pep
pep
regimen
base
avail
literatur
evid
obtain
anim
patient
studi
absenc
current
guidelin
pep
therapi
pep
agent
administ
day
last
exposur
base
incub
period
diseas
pep
therapi
associ
sever
advers
effect
although
mild
advers
event
revers
follow
complet
therapi
hcw
discontinu
treatment
due
advers
effect
frequenc
sever
durat
revers
advers
effect
import
consider
formul
prophylact
regimen
regard
pep
regimen
appear
reason
safe
choic
prophylaxi
merscov
exposur
studi
sever
limit
retrospect
studi
small
number
particip
inevit
select
unmeasur
confound
bia
could
complet
exclud
larg
outbreak
merscov
south
korea
hospit
administ
pep
hcw
highrisk
exposur
mer
patient
minim
select
bia
five
merscov
preisol
pneumonia
patient
sever
pneumonia
similar
c
valu
sourc
exposur
select
addit
compar
group
care
select
focu
degre
exposur
selfreport
use
determin
merscov
exposur
experi
hcw
might
recal
bia
best
method
evalu
novel
therapi
via
random
control
clinic
trial
set
howev
method
neither
feasibl
ethic
context
emerg
rel
uncommon
infecti
diseas
unexpect
outbreak
despit
small
number
particip
studi
largest
sampl
size
date
assess
effect
pep
therapi
prevent
merscov
infect
believ
pep
guidelin
merscov
infect
use
manag
outbreak
nonetheless
prospect
analys
random
clinic
studi
need
futur
